Lilly obtains FDA complete response letter for schizophrenia drug

Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of the NDA. Per the agency’s request, Lilly is preparing a proposed risk evaluation and mitigation strategy, which will be submitted in the near future.

Todd Durell, associate medical director for US neuroscience at Lilly, said: “We cannot speculate on the timing of a potential decision, but remain confident that, if approved, the long-acting depot formulation of olanzapine will offer an important option for treating this devastating and chronic illness.”

“This treatment has been approved for use in the EU and New Zealand under the trade name Zypadhera. Independent regulatory reviews are ongoing in other countries.”